The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | The case for separating G12D mutations in studying KRAS-mutant PDAC
Bach Ardalan, MD, University of Miami, Coral Gables, FL, comments on the frequency of KRAS mutations in pancreatic ductal adenocarcinoma (PDAC), which has a very high mutation rate. G12D is the most frequent KRAS variants, followed by G12V and G12R; these three mutations have different genomic profiles and survivorship rates, resulting in the need for separate cohorts in studies. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
